<?xml version="1.0" encoding="UTF-8"?>
<ref id="b21-1030522">
 <label>21.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Soiffer</surname>
    <given-names>RJ</given-names>
   </name>
   <name>
    <surname>Kim</surname>
    <given-names>HT</given-names>
   </name>
   <name>
    <surname>McGuirk</surname>
    <given-names>J</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT)</article-title>. 
  <source>Blood</source>. 
  <year>2016</year>;
  <volume>128</volume>(
  <issue>22</issue>):
  <fpage>505</fpage>.
 </mixed-citation>
</ref>
